Why Addiction Involves Both Reward and Metabolism
Addiction is not only a matter of willpower. Repeated exposure to highly rewarding substances or behaviors changes dopamine signaling in the brain’s reward circuits. At the same time, chronic use often disrupts cellular energy production, redox balance, and stress responses. Two very different compounds—NAD+ (and its precursors) and GLP-1 receptor agonists—are being studied because each appears to touch one of these layers.
Understanding both the central reward side and the metabolic side of addiction opens the possibility of complementary strategies. One approach aims to quiet the craving signal itself; the other aims to restore the cellular conditions that chronic use has degraded.
NAD+: Cellular Energy and Redox Support
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme required for hundreds of metabolic reactions. It accepts and donates electrons in energy production and serves as a substrate for enzymes that regulate DNA repair, inflammation, and gene expression. Levels of NAD+ tend to fall with age, chronic stress, and heavy alcohol or drug use.
In the context of addiction, the idea is straightforward: if brain and liver cells are energy-stressed and redox-imbalanced, restoring NAD+ may help stabilize function and reduce the intensity of withdrawal and cravings. Clinical observations dating back decades described intravenous NAD+ protocols used during detoxification. More recent case series and pilot work have reported reductions in craving scores, anxiety, and depression after NAD+ infusions in people with substance-use disorders.
One descriptive study of 50 poly-drug users found statistically significant drops in craving, anxiety, and depression after a course of NAD+-based infusions, with many patients testing negative for illicit substances during treatment. The evidence base is still limited—much of it comes from open-label or retrospective clinical experience rather than large randomized trials. Oral precursors such as NMN and NR are also being explored, including for acute alcohol exposure, but high-quality controlled data remain sparse.
The physiological rationale centers on supporting mitochondrial function, reducing oxidative stress, and potentially modulating dopamine-related pathways that depend on cellular energy status. When energy production in neurons is compromised, reward signaling and stress resilience both suffer. Restoring NAD+ pools is one way investigators have tried to address that layer of the problem.
GLP-1 Receptor Agonists: Quieting the Reward Signal
GLP-1 (glucagon-like peptide-1) is a gut hormone best known for regulating blood sugar and appetite. Medications that activate the GLP-1 receptor—semaglutide, liraglutide, and related drugs—were developed for type 2 diabetes and later for weight management. Patients and clinicians soon noticed reduced interest in alcohol and, in some cases, other substances.
The brain contains GLP-1 receptors in regions that process reward and motivation, including the nucleus accumbens and ventral tegmental area. Activating these receptors appears to dampen the dopamine surge that normally follows a rewarding cue. The result is often described as a quieter drive toward the addictive substance or behavior.
A randomized clinical trial of low-dose weekly semaglutide in adults with alcohol-use disorder found reduced alcohol consumed in a laboratory self-administration task, lower drinks per drinking day, and reduced weekly craving compared with placebo. Larger observational studies of hundreds of thousands of patients have linked GLP-1 receptor agonist use to lower risk of new substance-use diagnoses across alcohol, nicotine, cannabis, cocaine, and opioids. Among people who already had a disorder, use was associated with fewer hospitalizations, overdoses, and substance-related deaths. Semaglutide and liraglutide have shown the clearest signals in these analyses.
Because the effect appears across multiple substance classes, researchers suspect GLP-1 receptor activation is acting on a shared craving mechanism rather than on any single drug target. That makes the class of particular interest for addiction research beyond its original metabolic indications.
Why the Two Approaches Differ—and How They Might Complement Each Other
GLP-1 medications primarily act on central reward and satiety circuits. They reduce the pull of the substance itself. NAD+ primarily supports cellular energy metabolism and redox balance that are often impaired by chronic use. One targets the “wanting” signal; the other targets the metabolic wear-and-tear that accompanies addiction.
In theory, combining them could address both layers at once: lowering the intensity of craving while improving the cellular conditions under which recovery takes place. No large randomized trial has yet tested the combination specifically for addiction. The rationale is therefore biological rather than proven clinical synergy. Still, because the mechanisms do not directly overlap, the combination is biologically plausible and worth careful study under medical supervision.
Practically, a GLP-1 agonist might reduce the day-to-day intensity of food, alcohol, or other cravings, while NAD+ support could help during the higher-stress phases of detoxification or early abstinence of substances when cellular energy demands and oxidative stress are elevated. Any combined approach would require individualized medical oversight, laboratory monitoring, and integration with behavioral treatment.
Food, Alcohol, and Other Addictions
Food addiction and alcohol-use disorder share overlapping reward circuitry with other substance-use disorders. GLP-1 agonists already demonstrate clear effects on food intake and alcohol consumption in both randomized and observational data. Observational work further suggests broader effects across nicotine, opioids, and stimulants. NAD+ protocols have been used clinically across alcohol, opioids, and poly-drug dependence, mainly during detoxification and early recovery.
The shared biology of craving—dopamine signaling in mesolimbic pathways, stress-system activation, and impaired top-down control—makes both agents candidates for further testing across multiple forms of addiction. The strongest current human data remain in alcohol-use disorder and in people with co-occurring obesity or type 2 diabetes who were prescribed GLP-1 medications for metabolic reasons.
Practical Considerations and Medical Context
Neither NAD+ nor GLP-1 agonists are approved by the FDA specifically for treating addiction. GLP-1 medications carry established indications for diabetes and weight management; any use for substance-use disorder remains off-label. NAD+ infusions and high-dose precursors are likewise used outside formal labeled indications for addiction. Medical supervision, laboratory monitoring, and integration with counseling or behavioral support remain essential.
Side-effect profiles also differ. GLP-1 agonists commonly cause gastrointestinal symptoms and require careful dose titration. High-dose NAD+ infusions can produce flushing, chest tightness, or other transient sensations that usually resolve with slower administration. Individual health status, concurrent medications, and psychiatric history all influence risk-benefit calculations.
Hormone status, sleep, and overall metabolic health influence craving intensity and recovery capacity. When laboratory evaluation or peptide support is relevant, clinicians experienced in these areas can be reached through resources such as Vita Bella.
For individuals already addressing metabolic or hormone-related factors alongside recovery goals, the same clinical teams at Vita Bella can help coordinate monitoring and individualized plans.
References
1. Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(3):XXX-XXX. doi:10.1001/jamapsychiatry.2024.4789
2. Wang W, et al. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ. 2026;392:e083821. doi:10.1136/bmj-2025-083821
3. Wium-Andersen IK, et al. Association of GLP-1 receptor agonists with risk of alcohol-related outcomes: a nationwide cohort study. JAMA Psychiatry. 2024;81(11):1120-1128. doi:10.1001/jamapsychiatry.2024.2569
4. Blum K, et al. Complex NADASE infusions improve clinical outcome in substance use disorder: descriptive annotation in fifty cases. J Addict Res Ther. 2024;15(2):1-12.
5. Blum K, et al. Nicotinamide adenine dinucleotide (NAD+) and enkephalinase inhibition infusions significantly attenuate psychiatric burden sequalae in substance use disorder in fifty cases. J Reward Defic Syndr Addict Sci. 2022;8(1):1-10.
6. Klausen MK, et al. Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. EClinicalMedicine. 2025.
7. Jerlhag E. GLP-1 receptor agonists for alcohol and substance use disorders: preclinical mechanisms and clinical translation. Front Pharmacol. 2024.
